pharmaceutical investing AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
pharmaceutical investing EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
pharmaceutical investing Allergan Aesthetics Debuts AA Signature in the United States with SKIN360, Its First Multimodal Consultation Approach
pharmaceutical investing AbbVie Announces European Commission Approval of RINVOQ® for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
pharmaceutical investing AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
pharmaceutical investing AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® at Psych Congress 2026
pharmaceutical investing AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society Meeting
pharmaceutical investing Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
pharmaceutical investing AbbVie and BioLabs University of Toronto Open Applications for AbbVie Biotech Innovators Award at Life Sciences Ontario Forum
pharmaceutical investing AbbVie Named Official Pharmaceutical Sponsor of the PGA TOUR and 2026 Presidents Cup, Launches Birdies for Brain Health Campaign
pharmaceutical investing Allergan Aesthetics to Advance Scientific Dialogue on Skin Longevity, Aging Biology and Exosome Science at the 2026 Science of Skin Summit
pharmaceutical investing AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine
pharmaceutical investing AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Sankamap Expands Exploration Footprint at Fauro as Systematic Prospecting Advances and New Gold Targets Emerge
NevGold Defines Multiple High-Priority Drill Targets Including Key Feeder Structures at Nutmeg Mountain Gold Project, Idaho
Brixton Drills 58 m of 0.50 g/t AuEq and 17.6 m of 1.47 g/t AuEq in the Glenfiddich Zone at Camp Creek, Thorn Project
